A Call 13 da IMI-2  foi lançada em 30 de novembro de 2017 e as candidaturas para a 1.ª fase terminaram em 28 de fevereiro de 2018. As candidaturas para a 2ª fase encerram no dia 6 de setembro de 2018 aceitando propostas para os seguintes tópicos:

• Topic 1: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
• Topic 2: Genome-Environment Interactions in Inflammatory Skin Disease
• Topic 3: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
• Topic 4: Mitochondrial Dysfunction in Neurodegeneration
• Topic 5: Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
• Topic 6: A sustainable European induced pluripotent stem cell platform
• Topic 7: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
• Topic 8: Human tumour microenvironment immunoprofiling
• Topic 9: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
• Topic 10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
• Topic 11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
• Topic 12: Cardiovascular diseases and diabetes
• Topic 13: Respiratory diseases
• Topic 14: Neurodegenerative diseases
• Topic 15: Rare/orphan diseases

Trata-se de uma candidatura de 2 fases, cujo orçamento contará com 106.629.000 € financiados pelas empresas e Membros Associados da EFPIA e 116.421.000 € pelo IMI2.

Conheça os concursos lançados anteriormente e os projetos já financiados!

Website da IMI-2: http://www.imi.europa.eu/content/home

Publicado: 28 de abril de 2016